J Allergy Clin Immunol

AAAAI 2026: Biologic and oral immunotherapy compared head-to-head in multi-food allergy management

March 5, 2026

In the final stage of the OUtMATCH trial (NCT03881696), researchers found that multi‑food oral immunotherapy (mOIT) and omalizumab performed nearly identically in helping patients maintain real‑world ingestion of allergenic foods. Among 80 qualifying participants, daily‑diary success rates at 3 and 6 months were comparable (mOIT: 77% and 65%; omalizumab: 66% and 63%; p=0.10, p=0.77, respectively), and clinician evaluations through 12 months showed no significant group differences. Safety profiles were also similar, with only a few serious events reported. These findings were presented at the American Academy of Allergy, Asthma & Immunology annual meeting.

Source:

Chinthrajah R, et al. (2026, February). J Allergy Clin Immunol. Evaluation of dietary consumption feasibility following treatment with multi-food oral immunotherapy or omalizumab in OUtMATCH. https://www.jacionline.org/article/S0091-6749(25)02111-6/fulltext